advaxis
present
data
ongoing
phase
clinical
trial
sitc
princeton
globe
newswire
advaxis
nasdaq
adxs
biotechnology
company
focused
development
commercialization
immunotherapy
products
today
announced
present
eposter
annual
meeting
society
immunology
cancer
sitc
held
virtually
november
title
phase
study
vector
alone
combination
pembrolizumab
subjects
metastatic
cell
lung
cancer
nsclc
presenter
jonathan
goldman
university
california
los
angeles
santa
monica
ca
abstract
id
date
time
thursday
november
pm
pm
et
saturday
november
pm
pm
et
poster
available
advaxis
website
https
advaxis
advaxis
biotechnology
company
focused
development
commercialization
proprietary
antigen
delivery
products
immunotherapies
based
platform
technology
utilizes
live
attenuated
listeria
monocytogenes
lm
bioengineered
secrete
antigen
adjuvant
fusion
proteins
strains
believed
significant
advancement
immunotherapy
integrate
multiple
functions
single
immunotherapy
designed
access
direct
antigen
presenting
cells
stimulate
cell
immunity
activate
immune
system
equivalent
multiple
adjuvants
simultaneously
reduce
tumor
protection
tumor
microenvironment
enable
cells
eliminate
tumors
learn
advaxis
visit
connect
twitter
linkedin
facebook
youtube
investor
contact
tim
mccarthy
lifesci
advisors
llc
tim
